

ABIOMED INC  
Form 8-K  
June 09, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: June 3, 2010

(Date of earliest event reported)

**ABIOMED, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other Jurisdiction

of Incorporation)

04-2743260  
(IRS Employer

Identification Number)

Edgar Filing: ABIOMED INC - Form 8-K

**0-20584**

(Commission File Number)

**22 Cherry Hill Drive**

**Danvers, MA 01923**

(Address of Principal Executive Offices, including Zip Code)

**(978) 777-5410**

(Registrant's Telephone Number, including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On June 3, 2010, our compensation committee made its annual compensation determinations for our named executive officers. The committee determined the bonuses for fiscal 2010 performance, the salaries and target bonuses for fiscal 2011, and made the annual equity grants to executive officers. The compensation decisions made with respect to our executive officers who are serving as our principal executive officer, principal financial officer, or who were named executive officers in our most recent proxy statement were as follows:

<b>Executive Officer</b>	<b>Fiscal 2010 Bonus</b>	<b>Fiscal 2011 Salary</b>	<b>Target Fiscal 2011 Bonus (Percentage of salary)</b>	<b>Underlying Stock Options (4 year vesting)</b>	<b>Underlying Restricted Stock (3 year vesting)</b>	<b>Underlying Restricted Stock (Performance vesting)</b>
Michael R. Minogue, Chairman, CEO and President	\$ 538,965	\$ 405,153	100%	105,000	53,000	
Robert L. Bowen, Chief Financial Officer	\$ 150,000	\$ 295,800	50%	30,000	20,000	12,000
Andrew J. Greenfield, Vice President Healthcare Solutions	\$ 90,000	\$ 221,450	45%	25,000	15,000	10,000
David Weber, Chief Operating Officer	\$ 165,000	\$ 302,500	55%	50,000	25,000	17,000
William Bolt, Senior VP, Regulatory and Engineering	\$ 120,000	\$ 249,600	50%	30,000	20,000	12,000

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABIOMED, Inc.

By: /s/ **ROBERT L. BOWEN**  
**Robert L. Bowen**  
**Chief Financial Officer**

Date: June 9, 2010